The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
Abstract
PURPOSE: To study how adding oxaliplatin (l-OHP) to chronomodulated fluorouracil (5-FU)–leucovorin (LV) affected the objective response rate, as first-line treatment of metastatic colorectal cancer. PATIENTS AND METHODS: Two hundred patients from 15 institutions in four countries were randomly assigned to receive a 5-day course of chronomodulated 5-FU and LV (700 and 300 mg/m 2/d, respectively; peak delivery rate at 0400 hours) with or without l-OHP on the first day of each course (125 mg/m 2, as a 6-hour infusion). Each course was repeated every 21 days. Response was assessed by extramural review of computed tomography scans. RESULTS: Grade 3 to 4 toxicity from 5-FU–LV occurred in ≤ 5% of the patients (≤ 1% of the courses). Grade 3 to 4 diarrhea occurred in 43% of the patients given l-OHP (10% of the courses), and less than 2% of the patients had severe hematotoxicity. Thirteen percent of the patients had moderate functional impairment from peripheral sensory neuropathy. Sixteen percent of the patients receiving 5-FU–LV had an objective response (95% confidence interval [CI], 9% to 24%), compared with 53% of those receiving additional l-OHP (95% CI, 42% to 63%) (P < .001). The median progression-free survival time was 6.1 months with 5-FU–LV (range, 4.1 to 7.4 months) and 8.7 months (7.4 to 9.2 months) with l-OHP and 5-FU–LV (P = .048). Median survival times were 19.9 and 19.4 months, respectively. CONCLUSION: By chronomodulating 5-FU–LV, we were able to add l-OHP without compromising dose-intensities. l-OHP significantly improved the antitumor efficacy of this regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
Resection of Nonresectable Liver Metastases from Colorectal Cancer After Neoadjuvant Chemotherapy
Bismuth, H., Adam, R., Lévi, F., Farabos, C., Waechter, F., Castaing, D., Majno, P., & Engerran, L. (1996) · Annals of Surgery · doi:10.1097/00000658-199610000-00009 · Cited by 963
Self-citationde Gramont, A., Bosset, J. F., Milan, C., Rougier, P., Bouché, O., Etienne, P. L., Morvan, F., Louvet, C., Guillot, T., François, E., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.808 · Cited by 908
Poon, M. A., O'Connell, M. J., Moertel, C. G., Wieand, H. S., Cullinan, S. A., Everson, L. K., Krook, J. E., Mailliard, J. A., Laurie, J. A., & Tschetter, L. K. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1407 · Cited by 887
Fluorouracil: biochemistry and pharmacology.
Pinedo, H. M., & Peters, G. F. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.10.1653 · Cited by 834
Lokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., & Fryer, J. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.425 · Cited by 773
Lévi, F., Zidani, R., & Misset, J.-L. (1997) · The Lancet · doi:10.1016/s0140-6736(97)03358-8 · Cited by 701
Self-citationGehan, E. A. (1961) · Journal of Chronic Diseases · doi:10.1016/0021-9681(61)90060-1 · Cited by 667
Functional Identification of the Mouse Circadian Clock Gene by Transgenic BAC Rescue
Antoch, M. P., Song, E.-J., Chang, A.-M., Vitaterna, M. H., Zhao, Y., Wilsbacher, L. D., Sangoram, A. M., King, D. P., Pinto, L. H., & Takahashi, J. S. (1997) · Cell · doi:10.1016/s0092-8674(00)80246-9 · Cited by 665
Scheithauer, W., Rosen, H., Kornek, G. V., Sebesta, C., & Depisch, D. (1993) · BMJ · doi:10.1136/bmj.306.6880.752 · Cited by 654
Giacchetti, S., Itzhaki, M., Gruia, G., Adam, R., Zidani, R., Kunstlinger, F., Brienza, S., Alafaci, E., Bertheault-Cvitkovic, F., Jasmin, C., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008347829017 · Cited by 606
Self-citationPetrelli, N., Douglass, H. O., Herrera, L., Russell, D., Stablein, D. M., Bruckner, H. W., Mayer, R. J., Schinella, R., Green, M. D., & Muggia, F. M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1419 · Cited by 556
Erlichman, C., Fine, S., Wong, A., & Elhakim, T. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.3.469 · Cited by 503
Petrelli, N., Herrera, L., Rustum, Y., Burke, P., Creaven, P., Stulc, J., Emrich, L. J., & Mittelman, A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1559 · Cited by 450
Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J.-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., et al. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010489 · Cited by 434
Machover, D., Goldschmidt, E., Chollet, P. J. M., Metzger, G., Zittoun, J., Marquet, J., Vandenbulcke, J., Misset, J. L., Schwarzenberg, L., & Fourtillan, J. B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.5.685 · Cited by 397
Self-citationLévi, F. A., Zidani, R., Vannetzel, J.-M., Perpoint, B., Focan, C., Faggiuolo, R., Chollet, P., Garufi, C., Itzhaki, M., Dogliotti, L., et al. (1994) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/86.21.1608 · Cited by 396
Self-citationde Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., André, T., Varette, C., Raymond, E., Moreau, S., Le Bail, N., & Krulik, M. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00370-x · Cited by 386
Self-citationPhase I study of oxaliplatin in patients with advanced cancer
Extra, J. M., Espie, M., Calvo, F., Ferme, C., Mignot, L., & Marty, M. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00684890 · Cited by 343
Lévi, F., Misset, J.-L., Brienza, S., Adam, R., Metzger, G., Itzakhi, M., Caussanel, J.-P., Kunstlinger, F., Lecouturier, S., Descorps-Declère, A., et al. (1992) · Cancer · doi:10.1002/1097-0142(19920215)69:4<893::aid-cncr2820690410>3.0.co;2-x · Cited by 343
Self-citationBuroker, T. R., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Mailliard, J. A., Schaefer, P. L., Levitt, R., Kardinal, C. G., & Gesme, D. H. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.14 · Cited by 311
Bécouarn, Y., Ychou, M., Ducreux, M., Borel, C., Bertheault-Cvitkovic, F., Seitz, J. F., Nasca, S., Nguyen, T. D., Paillot, B., Raoul, J. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2739 · Cited by 301
Petrelli, N., Douglass, H. O., Herrera, L., Russell, D., Stablein, D. M., Bruckner, H. W., Mayer, R. J., Schinella, R., Green, M. D., Muggia, F. M., et al. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.185 · Cited by 280
Caussanel, J.-P., Lévi, F., Brienza, S., Misset, J.-L., Itzhaki, M., Adam, R., Milano, G., Hecquet, B., & Mathé, G. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.12.1046 · Cited by 253
Self-citationDíaz-Rubio, E., Sastre, J., Zaniboni, A., Labianca, R., Cortés-Funes, H., de Braud, F., Boni, C., Benavides, M., Dallavalle, G., & Homerin, M. (1998) · Annals of Oncology · doi:10.1023/a:1008200825886 · Cited by 228
Levi, F., Perpoint, B., Garufi, C., Focan, C., Chollet, P., Depres-Brummer, P., Zidani, R., Brienza, S., Itzhaki, M., Iacobelli, S., et al. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90073-o · Cited by 218
Self-citationPendyala, L., & Creaven, P. J. (1993) · PubMed · Cited by 209
Cunningham, D., Zalcberg, J. R., Rath, U., Oliver, I., van Cutsem, E., Svensson, C., Seitz, J. F., Harper, P., Kerr, D., & Perez-Manga, G. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010800 · Cited by 204
(1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.960 · Cited by 194
Piedbois, P., Buyse, M. E., Blijham, G. H., et al. (1994) · Journal of Clinical Oncology · Cited by 191
Mathé, G., Kidani, Y., Segiguchi, M., Eriguchi, M., Fredj, G., Peytavin, G., Misset, J. L., Brienza, S., de Vassals, F., Chenu, E., et al. (1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90003-6 · Cited by 187
Self-citationTashiro, T., Kawada, Y., Sakurai, Y., & Kidani, Y. (1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90004-8 · Cited by 171
DNA synthesis in human bone marrow is circadian stage dependent
Smaaland, R., Od, L., Lote, K., Sletvold, O., Sothern, R., & Bjerknes, R. (1991) · Blood · doi:10.1182/blood.v77.12.2603.2603 · Cited by 153
Köhne, C.-H., Schöffski, P., Wilke, H., Käufer, C., Andreesen, R., Ohl, U., Klaasen, U., Westerhausen, M., Hiddemann, W., Schott, G., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.418 · Cited by 152
Lévi, F., Zidani, R., Brienza, S., Dogliotti, L., Perpoint, B., Rotarski, M., Letourneau, Y., Llory, J., Chollet, P. J. M., Rol, A. L., et al. (1999) · Cancer · Cited by 134
Self-citationChemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
Köhne-Wömpner, C. H., Schmoll, H., Harstrick, A., & Rustum, Y. M. (1992) · PubMed · Cited by 106
Boughattas, N. A., Lévi, F., Fournier, C., Lemaigre, G., Roulon, A., Hecquet, B., Mathé, G., & Reinberg, A. (1989) · PubMed · Cited by 102
Self-citationBudd, G. T., Fleming, T. R., Bukowski, R. M., McCracken, J. D., Rivkin, S. E., OʼBryan, R. M., Balcerzak, S. P., & Macdonald, J. S. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.2.272 · Cited by 81
Labianca, R., Pancera, G., Aitini, E., et al. (1991) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058047 · Cited by 74
Bobbio-Pallavicini, E., Porta, C., Moroni, M., Spaghi, A., Casagranda, I., & Nastasi, G. (1993) · Journal of Chemotherapy · doi:10.1080/1120009x.1993.11739210 · Cited by 22
Cited by
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citationOxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Metadata
- Authors
- Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., Bertheaut-Cvitkovic, F., Larregain-Fournier, D., Le Rol, A., Walter, S., Adam, R., Misset, J. L., & Lévi, F.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-01-01
- Volume
- 18
- Issue
- 1
- Pages
- 136-136
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162313061
- Cited by
- 1,403
- References
- 46
- FWCI
- 36.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.